GLOW Legal Status, FDA 503A Category, and Compounding Access

The headline: under active review, restricted today

GLOW legal status is best read as a moving file with a firm present tense. The momentum is genuine: the FDA is actively re-examining this class of peptides, and an FDA Pharmacy Compounding Advisory Committee (PCAC) meeting is scheduled for July 23-24, 2026 to discuss several of these peptides as candidates for the 503A bulks list ^[13]. That is a scheduled evaluation, and compounded access to GLOW's constituents may expand in 2026 as that review proceeds.

The present-tense fact is just as real. As of today, the injectable peptides in the GLOW blend sit in FDA's 503A 'Category 2' — bulk substances FDA has identified as potentially presenting significant safety risks — which restricts compounding-pharmacy access ^[11][12]. Nothing on this page states any reclassification as already done, dated, or certain. This is general information about the regulatory landscape, not medical or legal advice.

What Category 2 means under sections 503A and 503B

U.S. drug compounding runs on two sections of the Federal Food, Drug, and Cosmetic Act. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, generally pursuant to a valid prescription for an individual patient. Section 503B covers FDA-registered 'outsourcing facilities' that may compound larger batches under cGMP-style oversight ^[11].

A compounder may use a bulk drug substance only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list. Substances not yet listed are evaluated by FDA through a public nomination process with input from PCAC. Under FDA's interim policy, Category 2 substances were nominated with enough information to evaluate but were identified as raising significant safety risks; they are not covered by the enforcement-discretion policy that applies to Category 1, and FDA has stated it would consider taking action against a compounder for compounding with a Category 2 substance ^[11][12]. Being discussed by PCAC is a step in evaluation, not a final listing decision.

Where each GLOW constituent stands today

The three legs of the blend do not share one status, and the strictest applies to the injected combination.

BPC-157 was placed in Category 2 for 503A compounding, effective with FDA's September 29, 2023 update to the nominated-substances list, citing concerns including potential immunogenicity for certain routes and complexities with peptide impurities and characterization ^[11]. It is not an FDA-approved drug. BPC-157 is on the published agenda of the July 23-24, 2026 PCAC meeting as a substance 'being considered for inclusion on the 503A Bulks List' — a scheduled discussion, not a decision ^[13].

TB-500 carries the same posture. FDA placed 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500' in Category 2, effective with the same September 29, 2023 update, citing immunogenicity concerns for certain routes and a lack of important safety information ^[11]. TB-500 also appears on the July 23-24, 2026 PCAC agenda as a candidate under consideration ^[13].

GHK-Cu requires two contexts kept separate. As a cosmetic ingredient, GHK-Cu labeled 'Copper Tripeptide-1' is used in topical skincare and is regulated under cosmetics rules, which do not require FDA pre-market approval of the ingredient ^[14]. As an injectable drug, FDA identified 'GHK-Cu (for injectable routes of administration)' as a bulk substance that may present significant safety risks and placed it in Category 2 for 503A compounding, effective with the September 29, 2023 update ^[11]. Importantly, GHK-Cu is not on the July 23-24, 2026 PCAC agenda; its injectable form remains in Category 2, separate from the cosmetic Copper Tripeptide-1 context ^[11][13].

How legally compounded peptide access works

When a compounded medication is obtained lawfully in the U.S., it follows one pathway. A patient is first evaluated by an appropriately licensed prescriber — in person or through a compliant telehealth encounter — who determines whether a compounded preparation is clinically appropriate. If it is, the prescriber issues a valid, patient-specific prescription. That prescription is then dispensed by a state-licensed 503A compounding pharmacy, or for office and batch use, sourced from an FDA-registered 503B outsourcing facility ^[11].

Telehealth is one channel for the prescriber-evaluation step, not a separate legal status: it is a route to a licensed-prescriber consultation and prescription, and it does not change which substances are eligible to be compounded or remove the need for a legitimate clinical evaluation and a valid prescription.

The ingredient-eligibility caveat is the one that governs this blend. A compounder may use a requested active ingredient only if that ingredient is eligible under the 503A/503B bulk-substance rules. Ingredients FDA has flagged for significant safety risks — which currently includes the injectable forms of GLOW's constituents — are not eligible for routine 503A compounding while that status stands. This page names no specific pharmacy, clinic, telehealth provider, or vendor, and offers no dosing, administration, or workaround guidance.

Access and regulatory questions

Is GLOW legal?

GLOW is not an FDA-approved drug. Its injectable constituents — BPC-157, TB-500, and injectable GHK-Cu — are in FDA's 503A Category 2 today, which restricts compounding-pharmacy access ^[11][12]. Topical Copper Tripeptide-1 (GHK-Cu) is a legal cosmetic ingredient in skincare, a separate context ^[14]. Access to the injectable peptides is under active FDA review and may expand in 2026, but no reclassification has been finalized.

Can you get GHK-Cu from a compounding pharmacy?

For the injectable drug form, not routinely today: FDA placed 'GHK-Cu (for injectable routes of administration)' in 503A Category 2 effective with its September 29, 2023 update, so it is not within FDA's enforcement-discretion policy for 503A compounding ^[11]. Topical Copper Tripeptide-1 in cosmetics is a different, legal context ^[14]. GHK-Cu is not on the July 23-24, 2026 PCAC agenda ^[13].

What is the FDA 503A status of GLOW?

GLOW is a non-standardized combination, and the strictest constituent status applies. BPC-157, TB-500, and injectable GHK-Cu are each in 503A Category 2 (effective with FDA's September 29, 2023 update), meaning FDA identified significant safety risks and they fall outside its enforcement-discretion policy ^[11][12]. BPC-157 and TB-500 are on the July 23-24, 2026 PCAC agenda as candidates under evaluation — a scheduled discussion, not a listing decision ^[13].